• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Sojourn Sevoflurane USP
    / Pharma Medis

    Active Ingredient

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Solution for Inhalation

    250 ml

    not in the basket chart


    The concentration of sevoflurane being delivered from a vaporizer during anesthesia should be known. This may be accomplished by using a vaporizer
    calibrated specifically for sevoflurane. The administration of general anesthesia must be individualized based on the patient’s response.
    Replacement of Desiccated CO2 Absorbents: When a clinician suspects that the CO2 absorbent may be desiccated, it should be replaced. The exothermic reaction that occurs with sevoflurane and CO2 absorbents is increased when the CO2 absorbents become desiccated, such as after an extended period of dry gas flow through the CO2 absorbent canisters.
    Pre-anesthetic Medication: No specific pre-medication is either indicated or
    contraindicated with sevoflurane. The decision as to whether or not to pre-medicate and the choice of pre-medication is left to the discretion of the anesthesiologist.
    Induction: Sevoflurane has a non-pungent odor and does not cause respiratory
    irritability; it is suitable for mask induction in pediatrics and adults.
    Maintenance: Surgical levels of anesthesia can usually be achieved with
    concentrations of 0.5 – 3 % sevoflurane with or without the concomitant use of
    nitrous oxide. Sevoflurane can be administered with any type of anesthesia circuit.
    See prescribing information for full details.


    For induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.


    Sevoflurane can cause malignant hyperthermia. It should not be used in patients with known sensitivity to sevoflurane or to other halogenated agents nor in patients with known or suspected susceptibility to malignant hyperthermia.

    Special Precautions

    See prescribing information for full details.

    Side Effects

    See prescribing information for full details.

    Drug interactions

    In clinical trials, no significant adverse reactions occurred with other drugs commonly used in the pre-operative period, including: central nervous system
    depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents,
    hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs.
    See prescribing information for full details.

    Pregnancy and Lactation

    Pregnancy: There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, sevoflurane should be used during pregnancy only if clearly needed.
    Nursing Mothers: The concentrations of sevoflurane in milk are probably of no clinical importance 24 hours after anesthesia. Because of rapid washout,
    sevoflurane concentrations in milk are predicted to be below those found with many other volatile anesthetics.
    See prescribing information for full details.


    In the event of overdosage, or what may appear to be overdosage, the following
    action should be taken: discontinue administration of sevoflurane, maintain a patent airway, initiate assisted or controlled ventilation with oxygen, and maintain adequate cardiovascular function.

    Piramal Healthcare, UK Ltd
    Licence holder